Oxibendazole inhibits prostate cancer cell growth
- Qiaoli Chen
- Yuhua Li
- Xiaoyu Zhou
- Runsheng Li
Published online on: December 11, 2017
Copyright: © Chen et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
Prostate cancer (PCa) is one of the most common malignancies among men and is the second leading cause of cancer‑associated mortality in the developed world. Androgen deprivation therapy (ADT) is the most common treatment for PCa. However, the majority of androgen‑sensitive PCa patients will eventually develop resistance to ADT and the disease will become androgen‑independent. There is, therefore, an immediate requirement to develop effective therapeutic techniques towards the treatment of recurrent PCa. Oxibendazole (OBZ) is an anthelmintic drug that has also shown promise in the treatment of malignancies. In the present study, the capability of OBZ to repress the growth of PCa cells was assessed in human androgen‑independent PCa 22Rv1 and PC‑3 cell lines. The growth of the 22Rv1 and PC‑3 cell lines, as assessed with a trypan blue exclusion assay, was markedly inhibited by OBZ treatment in vitro, with half‑maximal inhibitory concentration values of 0.25 and 0.64 µM, respectively. The mean size of 22Rv1 tumors in nude mice treated with OBZ (25 mg/kg/day) was 47.96% smaller than that of the control mice. Treatment with OBZ increased the expression of microRNA‑204 (miR‑204), as determined by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), and the level of p53 as determined with western blotting, two well‑characterized tumor suppressor genes. When miR‑204 expression was knocked down by introduction of an miR‑204 inhibitor, the inhibitory effect of OBZ was markedly reduced; however, when it was overexpressed, the inhibitory efficiency of OBZ was markedly higher, indicating that upregulation of miR‑204 is key for the efficacy of OBZ. Additionally, OBZ was demonstrated with RT‑qPCR to repress the expression of the androgen receptor, and by western blotting to reduce prostate‑specific androgen in 22Rv1 cells. The results suggest that OBZ has potential for clinical use in the treatment of recurrent PCa.